Axsome Therapeutics (AXSM) Cash from Operations (2015 - 2026)

Axsome Therapeutics has disclosed Cash from Operations across 12 years of filings, most recently posting 20700000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 20700000.0, up 52.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 70730000.0 (up 40.22% YoY), and the FY2025 annual result was 93405000.0, up 27.26% from the prior year.
• Cash from Operations came in at 20700000.0 for Q1 2026 at Axsome Therapeutics, down from 18653000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1046000.0 in Q3 2025 to a low of 55349000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 30110000.0 (2024), against an average of 29653294.12.
• Across the five-year window, Cash from Operations sank 818.52% in 2024 and soared 105.61% in 2025, its largest moves.
• Axsome Therapeutics' Cash from Operations stood at 27563000.0 in 2022, then fell by 10.15% to 30362000.0 in 2023, then climbed by 13.7% to 26202000.0 in 2024, then grew by 28.81% to 18653000.0 in 2025, then dropped by 10.97% to 20700000.0 in 2026.
• The last three Cash from Operations figures came in at 20700000.0 (Q1 2026), 18653000.0 (Q4 2025), and 1046000.0 (Q3 2025), per Business Quant data.